Calithera Biosciences Inc. (NASDAQ:CALA) shares rose 7% during mid-day trading on Wednesday . The company traded as high as $3.23 and last traded at $3.21, with a volume of 220,787 shares traded. The stock had previously closed at $3.00.

CALA has been the topic of a number of recent analyst reports. Wells Fargo & Co. restated a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. JMP Securities restated a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Finally, Zacks Investment Research downgraded shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $10.38.

The stock’s 50-day moving average price is $3.67 and its 200-day moving average price is $4.95. The company’s market cap is $59.52 million.

Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.05. Analysts expect that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current fiscal year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.